Comparative Pharmacology
Head-to-head clinical analysis: ATOVAQUONE AND PROGUANIL HYDROCHLORIDE versus BENZNIDAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATOVAQUONE AND PROGUANIL HYDROCHLORIDE versus BENZNIDAZOLE.
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE vs BENZNIDAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atovaquone is a mitochondrial electron transport inhibitor that selectively targets the cytochrome bc1 complex, disrupting pyrimidine synthesis in Plasmodium. Proguanil hydrochloride is a prodrug converted to cycloguanil, which inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis. The combination synergistically inhibits plasmodial replication.
Benznidazole is a nitroimidazole derivative that exerts trypanocidal activity against Trypanosoma cruzi. Its mechanism involves the reduction of the nitro group by a nitroreductase enzyme in the parasite, leading to the generation of toxic metabolites that damage parasite DNA and other cellular components.
250 mg atovaquone/100 mg proguanil hydrochloride (1 tablet) orally once daily for prophylaxis; 4 tablets (1000 mg/400 mg) orally once daily for 3 consecutive days for treatment.
5-7 mg/kg/day orally divided into two daily doses for 60 days. Maximum daily dose: 300 mg.
None Documented
None Documented
Clinical Note
moderateBenznidazole + Leflunomide
"The risk or severity of adverse effects can be increased when Benznidazole is combined with Leflunomide."
Clinical Note
moderateBenznidazole + Fingolimod
"Benznidazole may increase the immunosuppressive activities of Fingolimod."
Clinical Note
moderateBenznidazole + Tofacitinib
"Benznidazole may increase the immunosuppressive activities of Tofacitinib."
Clinical Note
moderatePimecrolimus + Benznidazole
Atovaquone: terminal half-life 2-3 days (67-83 hours); prolonged to 4-5 days in malaria due to drug accumulation. Proguanil: terminal half-life 12-21 hours; cycloguanil 14-21 hours.
Terminal elimination half-life is approximately 12 hours; may be prolonged in hepatic impairment.
Atovaquone: >94% excreted unchanged in feces via biliary elimination; renal excretion minimal (<1%). Proguanil: ~40-60% excreted renally as unchanged drug and metabolites (primarily cycloguanil and 4-chlorophenylbiguanide).
Primarily renal excretion of metabolites; <5% unchanged drug. Approximately 20% in feces.
Category A/B
Category C
Antiprotozoal
Antiprotozoal
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benznidazole."